Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's disease.

Sergey Shcherbinin,Amanda Morris,Ixavier A Higgins,Ilke Tunali,Ming Lu, Carmen Deveau,Sudeepti Southekal,Vikas Kotari,Cynthia D Evans,Anupa K Arora,Emily C Collins,Michael Pontecorvo,Mark A Mintun,John R Sims

Alzheimer's & dementia (New York, N. Y.)（2023）

引用 0|浏览12

暂无评分

摘要

Positron emission tomography (PET) evaluates candidates for Alzheimer's disease (AD) research. A positive tau PET scan is associated (≥93%) with amyloid positivity.A positive amyloid PET is not necessarily associated with tau positivity.Tau PET could be the sole diagnostic tool to confirm candidates for AD trials.

查看译文

关键词

alzheimer disease,amyloid,clinical trials

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要